Ribosomal protein L13 pseudogene 6 (RPL13P6)

Ribosomal protein L13 pseudogene 6 (RPL13P6) is a processed pseudogene—a DNA sequence bearing significant homology to the functional ribosomal protein L13 gene (RPL13), but containing mutations or alterations that prevent functional protein expression[3][8]. These pseudogenes are a natural consequence of genome evolution and are widely dispersed throughout the human genome[7][8]. Pseudogenes like RPL13P6 do not encode functional proteins and therefore do not have direct molecular functions, do not participate in canonical signaling pathways, and are not considered actionable targets for drugs or therapeutic modulation. There is no evidence to support a direct disease role, involvement in signal transduction, or utility as a drug target[7][5][8]. However, emerging research suggests some ribosomal protein pseudogenes may exert regulatory effects at the RNA level or act as competitive endogenous RNAs (ceRNAs), potentially influencing the expression of the parental gene in specific biological contexts[5]. These effects are indirect and not unique or functionally characterized for RPL13P6 specifically. Limitations and Corrections: RPL13P6 is a pseudogene, not an active therapeutic target, enzyme, transporter, receptor, or transcription factor[7][8]. There is no evidence linking RPL13P6 to clinical drugs, disease causation, or as a biomarker for therapy selection or monitoring. While pseudogenes can sometimes have regulatory RNA effects, there are no specific, validated data or clinical significance established for RPL13P6. Summary: Ribosomal protein L13 pseudogene 6 (RPL13P6) is a non-coding processed pseudogene with no known protein product, drug interactions, disease roles, or direct therapeutic relevance. It is not an incorrect spelling, but it is incorrect as a drug target due to its pseudogene status[3][7][8].

Other names

RPL13AP4RPL13_5_1409ribosomal protein L13a pseudogene 4RPL13P6[3]